Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care:: a multicentre, randomized, double-blind, controlled trial

被引:251
作者
Guyonnet, D.
Chassany, O.
Ducrotte, P.
Picard, C.
Mouret, M.
Mercier, C.-H.
Matuchansky, C.
机构
[1] Danone Res, F-91767 Palaiseau, France
[2] Dept Rech Clin, AP HP, Paris, France
[3] Univ Rouen Hosp, IFRMP23, EA 3234, Digest Tract Res Grp, Rouen, France
[4] Umanis Clin Res, F-92300 Levallois Perret, France
[5] Univ Paris 07, Lariboisierer St Louis Fac Med, F-75221 Paris 05, France
关键词
D O I
10.1111/j.1365-2036.2007.03362.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background Health-related quality of life (HRQoL) has been rarely evaluated as a primary endpoint in the assessment of the effect of probiotics on the irritable bowel syndrome (IBS). AimTo study the effects of fermented milk containing Bifidobacterium animalis DN-173 010 and yoghurt strains on the IBS in a multicentre, double-blind, controlled trial. Methods A total of 274 primary care adults with constipation-predominant IBS (Rome II) were randomized to consume for 6 weeks either the test fermented milk or a heat-treated yoghurt (control). HRQoL and digestive symptoms were assessed after 3 and 6 weeks on an intention-to-treat population of 267 subjects. Results The HRQoL discomfort score, the primary endpoint, improved (P < 0.001) in both groups at weeks 3 and 6. The responder rate for the HRQoL discomfort score was higher (65.2 vs. 47.7%, P < 0.005), as was the decrease in bloating score [0.56 +/- (s.d.)1.01 vs. 0.31 +/- 0.87, P = 0.03], at week 3 in the test vs. the control group. In those subjects with < 3 stools/week, stool frequency increased (P < 0.001) over 6 weeks in the test vs. control group. Conclusions This study suggests a beneficial effect of a probiotic food on discomfort HRQoL score and bloating in constipation-predominant IBS, and on stool frequency in subjects with < 3 stools/week.
引用
收藏
页码:475 / 486
页数:12
相关论文
共 64 条
[1]   Impact of irritable bowel syndrome (IBS) on health-related quality of life (HRQOL) [J].
Amouretti, M ;
Le Pen, C ;
Gaudin, AF ;
Bommelaer, G ;
Frexinos, J ;
Ruszniewski, P ;
Poynard, T ;
Maurel, F ;
Priol, G ;
El Hasnaoui, A .
GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE, 2006, 30 (02) :241-246
[2]  
[Anonymous], 2006, PAT REP OUTC MEAS US
[3]   Abdominal bloating [J].
Azpiroz, F ;
Malagelada, JR .
GASTROENTEROLOGY, 2005, 129 (03) :1060-1078
[4]   BIFIDOBACTERIUM FROM FERMENTED MILKS - SURVIVAL DURING GASTRIC TRANSIT [J].
BERRADA, N ;
LEMELAND, JF ;
LAROCHE, G ;
THOUVENOT, P ;
PIAIA, M .
JOURNAL OF DAIRY SCIENCE, 1991, 74 (02) :409-413
[5]   Prevalence of irritable bowel syndrome (IBS) and variability of diagnostic criteria [J].
Bommelaer, G ;
Poynard, T ;
Le Pen, C ;
Gaudin, AF ;
Maurel, F ;
Priol, G ;
Amouretti, M ;
Frexinos, J ;
Ruszniewski, P ;
El Hasnaoui, A .
GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE, 2004, 28 (6-7) :554-561
[6]  
Bouvier M., 2001, Bioscience and Microflora, V20, P43
[7]   Probiotics and irritable bowel syndrome: Rationale, putative mechanisms, and evidence of clinical efficacy [J].
Camilleri, M .
JOURNAL OF CLINICAL GASTROENTEROLOGY, 2006, 40 (03) :264-269
[8]   Validation of a specific quality of life questionnaire for functional digestive disorders [J].
Chassany, O ;
Marquis, P ;
Scherrer, B ;
Read, NW ;
Finger, T ;
Bergmann, JF ;
Fraitag, B ;
Geneve, J ;
Caulin, C .
GUT, 1999, 44 (04) :527-533
[9]   Investigating placebo effects in irritable bowel syndrome: A novel research design [J].
Conboy, LA ;
Wasserman, RH ;
Jacobson, EE ;
Davis, RB ;
Legedza, ATR ;
Park, M ;
Rivers, AL ;
Morey, EB ;
Nam, BH ;
Lasagna, L ;
Kirsch, I ;
Lembo, AJ ;
Kaptchuk, TJ ;
Kerr, CE .
CONTEMPORARY CLINICAL TRIALS, 2006, 27 (02) :123-134
[10]   Consensus report: clinical trial guidelines for pharmacological treatment of irritable bowel syndrome [J].
Corazziari, E ;
Bytzer, P ;
Delvaux, M ;
Holtmann, G ;
Malagelada, JR ;
Morris, J ;
Muller-Lissner, S ;
Spiller, RC ;
Tack, J ;
Whorwell, PJ .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2003, 18 (06) :569-580